Scientists have long used chemogenetics to study brains in the lab. A pilot trial for seizures is its first leap into medicine.
Flashing lights. Buzzing noises. A sudden wave of fear. For some people with epilepsy, these sensations herald an oncoming seizure.
Drugs can keep some seizures at bay, but over 30 percent of patients don’t respond to them, a statistic that hasn’t budged in decades. Frequent, uncontrolled seizures rob people of a normal life. They can’t drive or swim alone. Some struggle to stay in school, hold down jobs, or maintain relationships. And despite growing public awareness, stigma lingers.
For people with severe drug-resistant epilepsy, surgery is an option. If the seizures are associated with a local brain region, doctors can remove the tissue. It’s a drastic operation, but it isn’t rare. In 2024, over 2,000 patients elected to undergo the procedure. Depending on the brain region removed, surgery can control seizures in nearly 70 percent of patients, but they risk losing memory, language, and other cognitive abilities.
A new gene therapy could offer an alternative. In a clinical trial, three men who had lived with epilepsy for at least a decade saw monthly seizures drop over 90 percent. One remained seizure-free for a year.
In the trial, the team shuttled a gene into a small patch of the hippocampus, the source of their seizures. The gene produces a kind of protein “dimmer switch” in neurons. Normally silent, the protein springs into action when activated by an FDA-approved drug, allowing scientists to dial down the region’s electrical activity rather than shutting it off completely—something that’s not possible with current treatments.
Source link







